Skip to main content
main-content

Diabetes medications

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

About 50% attain type 2 glycemic targets with glargine 300 in real-world

Mature man injecting insulin in his abdomen

Initiating insulin glargine 300 U/mL could help half of those patients whose type 2 diabetes is inadequately controlled with oral antidiabetic medication to achieve their personal glycemic target within a year, real-world data suggest.

medwireNews top story

Lower gout risk with SGLT2 inhibitors vs GLP-1 receptor agonists

Gout

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

medwireNews top story

Insulin pumps may help stabilize glucose levels over the long term

Insulin pump

Continuous subcutaneous insulin infusion users have more stable glycated hemoglobin levels over the long term than multiple daily injection users with type 1 diabetes, a real-world study suggests.

medwireNews top story

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Kidneys

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

medwireNews top story

Further support for early combination therapy in type 2 diabetes

VERIFY trial results

Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.

medwireNews top story

Fasting C-peptide indicates hypoglycemia risk at basal insulin initiation

Blood test

Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.

medwireNews top story

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Heart and stethoscope

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Support for metformin cardioprotective effect

Heartbeat

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

medwireNews top story

Real-world data reassure on severe UTI risk with SGLT2 inhibition

Urine test strip

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

12-17-2019 | Insulin | Editorial | Article

How can we optimize titration with new basal insulins?

Nurse and Diabetes Educator Lori Berard highlights the advantages of “concentrated” insulins and outlines her recommendations for getting titration right for patients.

11-27-2019 | Nephropathy | Video | Article

The revolution is here: New treatments for diabetic kidney disease

WATCH | Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51).

09-24-2019 | Type 2 diabetes | Podcast | Article

How was it for you? The experts discuss EASD 2019

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits